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Abstract
The objective of this study was to compare the blood pool agent Gadomer with a small contrast agent for the visualization
of ultra-small, collateral arteries (diameter,1 mm) with high resolution steady-state MR angiography (SS-MRA) in a rabbit
hind limb ischemia model. Ten rabbits underwent unilateral femoral artery ligation. On days 14 and 21, high resolution SS-
MRA (voxel size 0.4960.4960.50 mm
3) was performed on a 3 Tesla clinical system after administration of either Gadomer
(dose: 0.10 mmol/kg) or a small contrast agent (gadopentetate dimeglumine (Gd-DTPA), dose: 0.20 mmol/kg). All animals
received both contrast agents on separate days. Selective intra-arterial x-ray angiograms (XRAs) were obtained in the ligated
limb as a reference. The number of collaterals was counted by two independent observers. Image quality was evaluated
with the contrast-to-noise ratio (CNR) in the femoral artery and collateral arteries. CNR for Gadomer was higher in both the
femoral artery (Gadomer: 7365 (mean 6 SE); Gd-DTPA: 4063; p,0.01) and collateral arteries (Gadomer: 1864; Gd-DTPA:
961; p=0.04). Neither day of acquisition nor contrast agent used influenced the number of identified collateral arteries
(p=0.30 and p=0.14, respectively). An average of 4.561.0 (day 14, mean 6 SD) and 5.361.2 (day 21) collaterals was found,
which was comparable to XRA (5.661.7, averaged over days 14 and 21; p.0.10). Inter-observer variation was 24% and 18%
for Gadomer and Gd-DTPA, respectively. In conclusion, blood pool agent Gadomer improved vessel conspicuity compared
to Gd-DTPA. Steady-state MRA can be considered as an excellent non-invasive alternative to intra-arterial XRA for the
visualization of ultra-small collateral arteries.
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Introduction
Therapeutic stimulation of the development of collateral arteries
from pre-existent arterioles (arteriogenesis) seems attractive as an
alternative or adjuvant treatment for patients with peripheral
arterial occlusive disease [1,2,3]. Further progress in the
development of such treatment strategies relies strongly on the
availability of non-invasive imaging methods that are able to
evaluate the efficacy of treatment in terms of vascular changes at
an early stage, even before clinical benefit can be noticed.
Therapeutic efficacy can be evaluated functionally, i.e. by
measuring perfusion recovery-related parameters in tissue distal to
the vascular lesion, or morphologically, i.e. by quantifying the
number and size of the collaterals formed. Contrast-enhanced MR
angiography (CE-MRA) has already proven to be a promising
non-invasive tool to visualize collateral arteries in various parts of
the body [4,5,6,7]. Preferably, CE-MRA images are acquired
during the first pass of the bolus, when the arterial concentration is
highest and veins are not yet enhanced. However, visualization of
small peripheral collateral arteries (diameter,1 mm) requires both
a very high spatial resolution and a large spatial coverage. Meeting
these requirements within the duration of the first pass period is a
challenge. Moreover, correct timing of the first-pass acquisition is
problematic in patients with severe stenoses and an extensive
network of collateral arteries, whose filling occurs very slowly and
varies considerably among and within patients [8,9].
An alternative is to acquire data during the post-bolus
equilibrium phase or steady state, which permits longer acquisition
times and therefore a higher spatial resolution. Due to its longer
acquisition time, steady-state MRA (SS-MRA) is less sensitive for
timing uncertainties than first-pass MRA (FP-MRA), as demon-
strated for the visualization of arterial stenoses in patients with
peripheral arterial occlusive disease [10]. To obtain sufficient
signal from the arteries, a high arterial contrast agent concentra-
tion over the entire duration of the acquisition is desired.
However, most currently available contrast agents are small (e.g.
gadopentetate dimeglumine (Gd-DTPA), molecular weight:
0.5 kDa) and extravasate rapidly after injection, resulting in both
a decrease in arterial signal intensity and an increase in
background enhancement. These problems may be solved by
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cular, thereby providing prolonged vascular enhancement [11].
Moreover, these so-called blood pool agents (BPAs) generally have
a higher T1 relaxivity compared to small contrast agents because
of their size [12], allowing reduction of contrast agent dose without
compromising signal-to-noise characteristics [13,14,15,16,17].
Various types of types of gadolinium-based BPAs have been
developed. One group consists of small BPAs that non-covalently
bind to plasma proteins, with the albumin-binding gadofosveset
trisodium as its principal, clinically approved example [18]. A
second group consists of medium-sized blood pool agents such as
P792 [19,20] and Gadomer [21], which are currently under
consideration for use in humans. Their value in diagnostics and
pretreatment assessment of peripheral and coronary arterial disease
has been demonstrated [10,11,22,23,24], yet their potential in the
visualization of ultra-small arteries required for the evaluation of
collateral artery formation remains to be explored.
In this study, we compared the blood pool agent Gadomer to
the small contrast agent Gd-DTPA for the visualization of small
collateral arteries with steady-state contrast-enhanced MRA in a
standardized rabbit hind limb ischemia model exhibiting arter-
iogenesis. For both contrast agents, image quality characteristics




This study was approved by the Maastricht University animal
ethics committee (approval ID 06-022). Ten male New Zealand
White rabbits (weight: approximately 3 kg) were included.
Occlusion of the right femoral artery was realized by placing
ligations 1 cm below the branch of the circumflex femoral artery
(CFA) and 1 cm above the bifurcation of the popliteal and tibial
arteries.
For all procedures, anesthesia was induced by intramuscular
injection of a combination of ketamine hydrochloride (50 mg/kg
body weight) and xylazin (8 mg/kg body weight). During the
procedures, the rabbits were intubated and ventilated with
isoflurane (2–3%) and oxygen. Post-operative analgesia was
provided during three days by daily intramuscular injections of
buprenorphine (0.09 mg/kg body weight). All invasive procedures
were performed under sterile conditions. After the last MR
measurements a lethal dose of pentobarbital (1 mL/kg body
weight) was administered intravenously.
X-ray angiography
On days 14 and 21 post ligation, XRA series of anterior-
posterior projections were recorded using a portable x-ray system
(BV Pulsera, Philips Medical Systems, Best, The Netherlands). In-
plane resolution was 0.260.2 mm, tube voltage was 72 kV and
frame rate was 12 s
21. An intra-arterial catheter was inserted into
the left carotid artery and positioned in the iliac artery of the
ligated limb, where a 5 mL bolus of non-ionic iodine contrast
agent (Omnipaque, Amersham Health, Eindhoven, The Nether-
lands, 240 mg iodine/mL) was injected at 5 mL/s, followed by a
saline flush.
MR angiography
Within one hour after XRA, the animals were imaged in supine
position on a clinical 3.0 Tesla MRI system equipped with a 5-
element phased-array cardiac coil (Philips Medical Systems, Best,
The Netherlands). The rabbits were placed in a custom-made
fixating box to standardize animal positioning.
The steady-state MRA (SS-MRA) protocol consisted of a T1-
weighted spoiled fast gradient echo sequence. Field-of-view (FOV)
in the cranio-caudal read-out direction was 250 mm and
rectangular FOV was 80%. Parallel imaging acceleration (SENSE)
factor in the right-left direction was 2. Acquisition was started after
a delay of two minutes. Matrix size was 5126410 with 282
overlapping coronal slices (slice thickness 0.5 mm). Measured
voxel size was 0.4960.4960.50 mm
3. TR/TE/FA were 10.5 ms/
2.7 ms/25u. Acquisition time was 5 minutes.
Contrast agents
To all animals both a small extravascular agent (Gd-DTPA) and
a medium-sized blood pool agent (Gadomer) were administered.
Gadomer (Schering Pharma AG, Berlin, Germany) is a dendritic
gadolinium chelate, containing 24 Gd
3+ ions. It has a molecular
weight of 17 kDa. Gd-DTPA and Gadomer were administered in
a randomized order on separate days. The contrast agent (vial
concentration 0.5 M, injected volume approximately 0.3 mL or
0.6 mL, for Gadomer and Gd-DTPA, respectively) was injected at
0.05 mL/s into an ear vein, followed by 2 mL saline flush injected
at the same rate.
The contrast agent dose was selected by estimating signal
enhancement during the course of SS-MRA acquisition based on a
biexponential approximation of contrast agent concentration
determined in a previous study [25] for a range of doses. A full
description of the procedure is found in Appendix S1; see also
Figure S1. The optimal dose for Gadomer was 0.10 mmol Gd/kg.
For Gd-DTPA, maximum signal enhancement was obtained with
a dose of 0.50 mmol Gd/kg. However, this was considered too
high, and the difference among doses in the range of 0.20–
0.50 mmol Gd/kg was small. We therefore selected the lowest
dose in this range (0.20 mmol/kg). For these doses, the average
concentration during image acquisition is 0.8 mM for Gadomer
and 1.3 mM for Gd-DTPA.
Image analysis
Image processing. From the dynamic XRA image series a
maximum intensity projection (MIP) was calculated in MATLAB
(The MathWorks, Natick, MA, version R2007b) over the time
frames that exhibited arterial enhancement. The resulting images
were used for collateral identification. The MR angiograms were
viewed in the image processing application OsiriX (version 3.7),
using the source images for signal intensity measurements. For
collateral identification, coronal maximum intensity projections
over a limited range of slices (partial MIPs) were used. The
thickness and location of the slab, as well as the display contrast
and brightness levels could be adjusted in real time to obtain
optimal depiction of the collateral trajectories and varied
depending on image quality and vascular anatomy.
Collateral quantification. The number of collaterals was
counted on the partial MIP by two independent observers using
the Longland definition [26], which requires identification of the
stem, mid- and re-entry zone. A distinction was made between
collaterals stemming from the deep femoral artery (DFA) and CFA
[27]. To evaluate whether the same collateral arteries were
identified between measurements, the observers provided a
schematic representation of the course of the identified
collaterals, including the approximate position of the stem and
re-entry point.
Arteries were separated from veins based on their size, location,
and branching point. Due to evident differences in image quality,
the observers were not blinded for contrast agent.
Image quality. Signal intensities (SI) were measured in the
femoral artery (proximal of the occlusion), a collateral artery
MR Angiography of Collateral Arteries
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collateral. Noise was estimated by calculating the standard
deviation of a relatively homogeneous part of adjacent muscle
tissue (SDmuscle). From these data signal-to-noise (SNR) and








Interobserver agreement of the collateral artery counting was
assessed with a between-observer coefficient of variation. The
difference in number of collaterals between XRA and MRA was
tested using a paired Wilcoxon signed rank test. A repeated
analysis of variance (ANOVA) was used to test whether day of
acquisition or contrast agent used (for MRA) had an influence on
the number of identified collateral arteries. Independent sample
two-sided Student’s t-tests were performed to test the difference in
SNR and CNR between Gadomer and Gd-DTPA for the femoral
Figure 1. Contrast-enhanced MR angiograms with Gadomer and Gd-DTPA. Partial maximum intensity projections (MIPs) in the anterior-
posterior direction of steady-state MR angiograms (SS-MRA) for Gadomer (left column) and Gd-DTPA (right column). On the thin-slab MIPs (thickness
3–4 slices, panels a and b), collaterals could be discerned for both contrast agents. Thick slab MIPs (.20 slices; panels c and d) show superior
depiction of vessels with Gadomer. For Gd-DTPA, the images were blurred. Panels e and f show the corresponding x-ray angiograms (XRA). 1: femoral
artery; 2: circumflex femoral artery; 3: deep femoral artery; 4: tibial artery; 5: popliteal artery; 6: popliteal vein; 7: iliac artery; 8: iliac vein. * indicate
collaterals. The ligation is indicated with the arrow in the XRA images. All images were acquired on day 21.
doi:10.1371/journal.pone.0016159.g001
MR Angiography of Collateral Arteries
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Effects were considered significant for p,0.05.
Results
Image quality
On the steady-state MR angiograms, both arteries and veins
were enhanced, but the spatial configuration of the vessels and the
high spatial resolution of the angiograms allowed distinction of
arteries from veins (see Figure 1 and Videos S1 and S2). For
Gadomer, thick-slab MIPs (thickness.10 mm) provided the best
overview of the vascular system, but for Gd-DTPA these images
appeared too blurred to be of use. On thin-slab MIPs
(thickness,5 mm), the advantage of Gadomer was less pro-
nounced. Although the femoral and collateral arteries appeared
more conspicuous with Gadomer, contrast between artery and
background tissue was sufficiently high to identify the complete
trajectories of the collaterals for both contrast agents.
SNR was higher in both the femoral and collateral arteries for
Gadomer compared to Gd-DTPA (Figure 2). This improvement
was significant in the femoral artery (p,0.01), and had the same,
yet statistically non-significant trend in the collateral arteries
(p=0.10). CNR was significantly higher in both femoral and
collateral arteries when Gadomer was used (femoral artery:
p,0.01; collateral artery: p=0.04). ROI size was typically 10
voxels in the femoral artery and 3 voxels in the collateral artery.




Table 1 lists the results of the collateral quantification. On day
14, an average of 4.9 and 4.3 collaterals was found for Gadomer
and Gd-DTPA, respectively, and on day 21 an average of 5.8
(Gadomer) and 4.5 (Gd-DTPA) arteries were identified. Analysis
of variance revealed that neither day of acquisition nor contrast
agent used influenced the number of identified collateral arteries
(p=0.30 and p=0.14, respectively). Although the animals were
positioned in a custom-made fixating box, it was not feasible to
perform 1-to-1 comparison of the collaterals found with either
contrast agent due to difficulties in determining the exact course of
the collateral arteries. Inter-observer variation in the number of
identified collaterals on SS-MRA was 24% and 18% for Gadomer
and Gd-DTPA, respectively, meaning that the difference between
observers is approximately one collateral artery. Identification of
the exact points of branching and re-entering appeared to be
highly subjective, and no conclusions could be drawn from the
schematic vessels courses.
The number of collateral arteries found with XRA increased
between days 14 and 21 (day 14: 5.161.7 (mean 6 SD); day 21:
6.361.8; p=0.04). The number of collateral arteries found with
XRA was equal to the number found with MRA (p=0.08). For
XRA, most collaterals originated from the deep femoral arteries
(120 out of 172 or 70%), whilst for MRA only 50% (77 out of 153)
stemmed from the DFA.
Discussion
Current findings
To our knowledge, this is the first study that directly compares
the efficacy of the blood pool agent Gadomer with Gd-DTPA for
the visualization of ultra-small collateral arteries. The number of
collaterals identified on the steady-state images was equal for the
two contrast agents, and closely mirrored the number of collaterals
identified on high resolution invasive X-ray angiograms. Contrast
enhancement in collateral arteries in terms of CNR and therefore
vessel conspicuity, was superior for Gadomer compared to
Gd-DTPA.
Blood pool agents versus small contrast agents
The use of Gadomer resulted in a considerably higher contrast
between collateral arteries and background compared to Gd-
DTPA in the SS-MRA images. Because of this improved image
quality, thick-slab MIPs could be used to get a better overview of
the vessel trajectories, which notably facilitated the localization of
collateral arteries, thus making it less time-consuming. For Gd-
DTPA, the value of these thick-slab MIPs was limited, because
background enhancement became problematic for slabs thicker
than approximately 8 slices (5 mm). Moreover, thick-slab MIPs
may suggest connections between vessels which are in fact
crossings of different vessels. Therefore, to follow the trajectory
of the collateral artery from stem to re-entry zone, thin-slab MIPs
were used, which combined the favorable contrast-to-noise
characteristics of source images with the improved overview
related to MIPs. Using thin-slab MIPs for the actual identification
diminished the disadvantage for Gd-DTPA, as the contrast
between collaterals and background was still high enough to
identify an equal number of collaterals compared to XRA, leaving
little room for improvement with Gadomer.
Figure 2. SNR and CNR in femoral and collateral artery. Mean signal-to-noise (SNR, panel a) and contrast-to-noise ratio (CNR, panel b) in the
femoral artery and a collateral artery originating from the deep femoral artery in the steady-state MR angiograms for Gadomer (white) and Gd-DTPA
(black). Error bars indicate standard error of the mean. Significant differences between contrast agents (p,0.05) are indicated with *. Data were
averaged over days 14 and 21 post ligation.
doi:10.1371/journal.pone.0016159.g002
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extravasation. For Gadomer, the extravasation rate is approximately
10 times lower compared to Gd-DTPA [28], which has two positive
effects for angiography. First, a slower decrease in blood concentra-
tion during the distribution phasecouldbe observed, as demonstrated
in a previous study [25]. Second, the lower extravasation rate resulted
in decreased contrast agent concentrations in the background tissue
[28]. To obtain the same vascular contrast enhancement, the dose of
Gadomercouldbereducedbyafactor2comparedtoGd-DTPAdue
to a higher r1 value for Gadomer.
Although Gadomer has already been safely used for angiogra-
phy in humans [22], it is not yet approved. The potential
advantage of Gadomer over the clinically approved BPA
gadofosveset trisodium is that it is remains intravascular due to
its intrinsic structure rather than to its binding affinity with
albumin. During first-pass, a large (74% [17]) fraction of
gadofosveset trisodium is not yet bound and extravasates more
rapidly, as gadofosveset trisodium has a size comparable to Gd-
DTPA. Moreover, at 3 Tesla, compared to gadofosveset,
Gadomer has a higher r1 (Gadomer: 13 L mmol
21 s
21; gadofos-
veset: 9.9 L mmol
21 s
21) and a lower r2 (Gadomer:
25 L mmol
21 s
21; gadofosveset: 60 L mmol
21 s2
1), which may
favor Gadomer for imaging at 3 Tesla.
MRA versus XRA
In addition to the advantages regarding invasiveness and
ionizing radiation, MRA has the advantage of the availability of
3D data compared to 2D XRA, which is a one-directional
projection. On these projections no distinction can be made
between arteries that branch off or cross other arteries, which
hinders the identification of stem and re-entry zones. A second
disadvantage of XRA is the high signal from bone structures. In
clinical practice, this problem is usually solved by using digital
subtraction of pre- and post-contrast images. In our study,
vasospasms and animal movement due to contrast injection
regularly resulted in blurred images which were less suited for
collateral identification. Consequently, the proximity of the femur
to the mid and re-entry zone of collaterals stemming from the
circumflex femoral artery resulted in the identification of fewer
collaterals stemming from the CFA on XRA images compared to
MRA. Although the spatial resolution achieved with MRA is
generally lower than with XRA, MRA compared well to XRA for
both contrast agents and the total number of collaterals visualized
on MRA was comparable to that of XRA.
Conclusion
The blood pool agent Gadomer has great potential in the
visualization of small collateral arteries with steady-state contrast-
enhanced MRA. The total number of identified collaterals was
equal to XRA. Although no difference between Gadomer and Gd-
DTPA in number of identified collaterals or interobserver
variability was found in this study, the enhanced collateral artery
conspicuity appreciably facilitated the identification of collateral
arteries with Gadomer compared to Gd-DTPA, while the dose
was reduced.
Supporting Information
Figure S1 Signal enhancement time course. Signal
enhancement time course for a range of contrast agent doses for
Gadomer (panel a; range: 0.05–0.20 mmol/kg) and Gd-DTPA
(panel b; range 0.10–0.50 mmol/kg). Grey shaded regions indicate
the acquisition window for steady-state MRA in this study.
(TIF)
Appendix S1 Dose optimization. Procedure for the selection
of the optimal dose for Gadomer and Gd-DTPA.
(DOC)
Video S1 MRA with Gadomer. Dynamic overview of a
typical MRA data set with Gadomer. Partial maximum intensity
projections in the anterior-posterior direction of steady-state MR
angiograms (SS-MRA) were obtained at varying positions. Slab
thickness was 2 cm.
(AVI)
Video S2 MRA with Gd-DTPA. Dynamic overview of a
typical MRA data set with Gd-DTPA. Partial maximum intensity
projections in the anterior-posterior direction of steady-state MR
angiograms (SS-MRA) were obtained at varying positions. Slab
thickness was 2 cm.
(AVI)
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